Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis
Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis · 2025
DOI: 10.1177/08968608241274106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2025. Verfasst von Mario Bonomini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti-Pescara, Chieti, Italy. Hauptthemen laut MEDLINE: Dialysis Solutions, Kidney Failure, Chronic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Peritoneal dialysis adoption and technique survival is affected by limitations related to peritoneal membrane longevity and metabolic alterations. Indeed, almost all peritoneal dialysis fluids exploit glucose as an osmotic agent that rapidly diffuses across the peritoneal membrane, potentially resulting in metabolic abnormalities such as hyperglycemia, hyperinsulinemia, obesity, and hyperlipidemia. Moreover, glucose-degradation products generated during heat sterilization, other than glucose itself, induce significant morphological and functional changes in the peritoneum leading to ultrafiltration failure. The partial substitution of glucose with osmotic agents characterized by a better local and systemic biocompatibility has been suggested as a potential strategy to innovate peritoneal dialysis fluids. The approach aims to minimize glucose-associated toxicity, preserving the peritoneal membrane welfare and counteracting common comorbidities. In this work, we report the clinical trial design of ELIXIR, a phase III randomized, controlled, blinded outcome assessment study comparing Xylocore ® , an innovative formulation based on Xylitol and l-carnitine, to standard glucose-based regimens, in end-stage kidney disease patients treated with continuous ambulatory peritoneal dialysis; 170 patients will be randomized (1:1) to receive XyloCore ® or to continue their pre-randomization peritoneal dialysis (PD) therapy with glucose-only PD solutions, for 6 months. The primary study's objective is to demonstrate the noninferiority of XyloCore ® in terms of Kt/V urea, for which a clinically acceptable noninferiority margin of −0.25 has been determined, assuming that all patients will be treated aiming to a minimum target of 1.7 and an optimal target of 2.0.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti-Pescara, Chieti, Italy.
- School of Medicine, Faculty of Medicine and Health Sciences, Keele University, Staffordshire, UK.
- MVZ DaVita Rhein-Ruhr GmbH, Duesseldorf, Germany.
- Department of Internal Medicine, University of Perugia, Perugia, Italy.
- Division of Renal Medicine, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
- Medical Unit Renal Medicine, Karolinska University Hospital, and CLINTEC, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Simon Davies, Mark Lambie, Gianpaolo Reboldi, Olof Heimburger, Tommaso Prosdocimi, Arduino Arduini
Zitieren
APA
Bonomini, M., Davies, S., Kleophas, W., Lambie, M., Reboldi, G., Liberato, L. D., Divino-Filho, J. C., Heimburger, O., Ortiz, A., Povlsen, J., Iacobelli, M., Prosdocimi, T., & Arduini, A. (2025). Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. https://doi.org/10.1177/08968608241274106
Vancouver
Bonomini M, Davies S, Kleophas W, Lambie M, Reboldi G, Liberato LD, et al. Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 2025. doi:10.1177/08968608241274106
BibTeX
@article{Bonomini2025,
author = {Bonomini, Mario and Davies, Simon and Kleophas, Werner and Lambie, Mark and Reboldi, Gianpaolo and Liberato, Lorenzo Di and Divino-Filho, Josè Carolino and Heimburger, Olof and Ortiz, Alberto and Povlsen, Johan and Iacobelli, Massimo and Prosdocimi, Tommaso and Arduini, Arduino},
title = {Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis},
journal = {Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis},
year = {2025},
doi = {10.1177/08968608241274106}
}
EUVIMED